(rac)-8-endo/exo-3-benzyl-8-methyl-3-aza-bicyclo[3.2.1]octan-8-ol | 1331846-58-2

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 哌啶类
• 英文名称: (rac)-8-endo/exo-3-benzyl-8-methyl-3-aza-bicyclo[3.2.1]octan-8-ol
• 英文别名: 3-benzyl-8-methyl-3-azabicyclo[3.2.1]octan-8-ol；3-Benzyl-8-methyl-3-azabicyclo[3.2.1]octan-8-ol
• CAS: 1331846-58-2
• 化学式: C₁₅H₂₁NO
• 分子量: 231.338
• InChiKey: IRGRGNINMVLGBC-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.1
• 重原子数：
  17
• 可旋转键数：
  2
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.6
• 拓扑面积：
  23.5
• 氢给体数：
  1
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  (rac)-8-endo/exo-3-benzyl-8-methyl-3-aza-bicyclo[3.2.1]octan-8-ol 在 palladium 10% on activated carbon 氢气 作用下， 以 甲醇 为溶剂， 生成 8-methyl-3-azabicyclo[3.2.1]octan-8-ol
  参考文献：
  名称：

  [EN] PYRROLOPYRIMIDINE COMPOUNDS AS INHIBITORS OF CDK4/6
  [FR] COMPOSÉS DE LA PYRROLOPYRIMIDINE UTILISÉS EN TANT QU'INHIBITEURS DES CDK4/6

  摘要：

  本发明涉及一种新型吡咯吡嘧啶化合物，其化学式为（I），其中R1、R2Y、R4、R8-R11、A和L的定义如下，以及其盐，包括其药用可接受盐。本发明的化合物是CDK4/6抑制剂，可用于治疗由CDK4/6介导的疾病和紊乱，如癌症，包括袍细胞淋巴瘤、脂肪肉瘤、非小细胞肺癌、黑色素瘤、鳞状细胞食管癌和乳腺癌。本发明还涉及包含本发明化合物的药物组合物。此外，本发明还涉及通过使用本发明化合物或包含本发明化合物的药物组合物来抑制CDK4/6活性和治疗相关疾病的方法。

  公开号：

  WO2011101409A1
• 作为产物：
  描述：

  甲基溴化镁 、 3-苄基-3-氮杂双环[3.2.1]辛-8-酮 在 水 、 氯化铵 、 sodium hydroxide 作用下， 以 乙醚 为溶剂， 以51%的产率得到(rac)-8-endo/exo-3-benzyl-8-methyl-3-aza-bicyclo[3.2.1]octan-8-ol
  参考文献：
  名称：

  [EN] PYRROLOPYRIMIDINE COMPOUNDS AS INHIBITORS OF CDK4/6
  [FR] COMPOSÉS DE LA PYRROLOPYRIMIDINE UTILISÉS EN TANT QU'INHIBITEURS DES CDK4/6

  摘要：

  本发明涉及一种新型吡咯吡嘧啶化合物，其化学式为（I），其中R1、R2Y、R4、R8-R11、A和L的定义如下，以及其盐，包括其药用可接受盐。本发明的化合物是CDK4/6抑制剂，可用于治疗由CDK4/6介导的疾病和紊乱，如癌症，包括袍细胞淋巴瘤、脂肪肉瘤、非小细胞肺癌、黑色素瘤、鳞状细胞食管癌和乳腺癌。本发明还涉及包含本发明化合物的药物组合物。此外，本发明还涉及通过使用本发明化合物或包含本发明化合物的药物组合物来抑制CDK4/6活性和治疗相关疾病的方法。

  公开号：

  WO2011101409A1

文献信息

• BRIDGED PIPERIDINE DERIVATIVES
  申请人：Baumann Karlheinz

  公开号：US20120225884A1

  公开（公告）日：2012-09-06

  The present invention relates to compounds of formula I hetaryl I, hetaryl II, R 1 , R 2 , R 3 , Y, m, and o or to pharmaceutically active acid addition salts thereof. The present compounds of formula I are modulators for amyloid beta and thus, they may be useful for the treatment or prevention of a disease associated with the deposition of β-amyloid in the brain, in particular Alzheimer's disease, and other diseases such as cerebral amyloid angiopathy, hereditary cerebral hemorrhage with amyloidosis, Dutch-type (HCHWA-D), multi-infarct dementia, dementia pugilistica and Down syndrome.

  本发明涉及式Ihetaryl I、hetaryl II、R1、R2、R3、Y、m和o的化合物，或其药用活性酸盐。式I的这些化合物是淀粉样蛋白β的调节剂，因此它们可能对治疗或预防与大脑中β-淀粉样蛋白沉积相关的疾病有用，特别是阿尔茨海默病，以及其他疾病，如脑淀粉样血管病、遗传性淀粉样脑出血、荷兰型（HCHWA-D）、多梗死性痴呆、拳击性痴呆和唐氏综合征。
• PYRROLOPYRIMIDINE COMPOUNDS AS INHIBITORS OF CDK4/6
  申请人：Brain Christopher Thomas

  公开号：US20130150342A1

  公开（公告）日：2013-06-13

  The invention is directed to novel pyrrolopyrimidine compounds of formula (I) wherein R 1 , R 2Y , R 4 , R 8 -R 11 , A and L are defined herein and to salts, including pharmaceutically acceptable salts thereof. The compounds of the present invention are CDK4/6 inhibitors and could be useful in the treatment of diseases and disorders mediated by CDK4/6, such as cancer, including mantle cell lymphoma, liposarcoma, non small cell lung cancer, melanoma, squamous cell esophageal cancer and breast cancer. The invention is further directed to pharmaceutical compositions comprising a compound of the invention. The invention is still further directed to methods of inhibiting CDK4/6 activity and to the treatment of disorders associated therewith using a compound of the invention or a pharmaceutical composition comprising a compound of the invention.

  本发明涉及公式（I）的新型吡咯并嘧啶化合物，其中R1，R2Y，R4，R8-R11，A和L在此处定义，并且包括其盐，包括医药上可接受的盐。本发明的化合物是CDK4/6抑制剂，可用于治疗由CDK4/6介导的疾病和障碍，如癌症，包括曼托细胞淋巴瘤，脂肪肉瘤，非小细胞肺癌，黑色素瘤，鳞状细胞食管癌和乳腺癌。本发明还涉及包含本发明化合物的制药组合物。本发明还涉及使用本发明化合物或包含本发明化合物的制药组合物来抑制CDK4/6活性和治疗与之相关的障碍的方法。
• Pyrrolopyrimidine compounds as inhibitors of CDK4/6
  申请人：Brain Christopher Thomas

  公开号：US08957074B2

  公开（公告）日：2015-02-17

  The invention is directed to novel pyrrolopyrimidine compounds of formula (I) wherein R1, R2Y, R4, R8-R11, A and L are defined herein and to salts, including pharmaceutically acceptable salts thereof. The compounds of the present invention are CDK4/6 inhibitors and could be useful in the treatment of diseases and disorders mediated by CDK4/6, such as cancer, including mantle cell lymphoma, liposarcoma, non small cell lung cancer, melanoma, squamous cell esophageal cancer and breast cancer. The invention is further directed to pharmaceutical compositions comprising a compound of the invention. The invention is still further directed to methods of inhibiting CDK4/6 activity and to the treatment of disorders associated therewith using a compound of the invention or a pharmaceutical composition comprising a compound of the invention.

  本发明涉及一种新型的吡咯吡嗪化合物，其化学式为(I)，其中R1、R2Y、R4、R8-R11、A和L的定义如本文所述，并且包括其盐，包括药学上可接受的盐。本发明的化合物是CDK4/6抑制剂，可用于治疗由CDK4/6介导的疾病和障碍，如癌症，包括曼托细胞淋巴瘤、脂肪肉瘤、非小细胞肺癌、黑色素瘤、鳞状细胞食管癌和乳腺癌。本发明还涉及包含本发明化合物的制药组合物。本发明还涉及使用本发明化合物或包含本发明化合物的制药组合物来抑制CDK4/6活性和治疗相关障碍的方法。
• [EN] 2-AMINOQUINAZOLINES AS LRRK2 INHIBITORS, PHARMACEUTICAL COMPOSITIONS, AND USES THEREOF<br/>[FR] 2-AMINOQUINAZOLINES SERVANT D'INHIBITEURS DE LRRK2, COMPOSITIONS PHARMACEUTIQUES ET LEURS UTILISATIONS
  申请人：MERCK SHARP & DOHME

  公开号：WO2022051337A1

  公开（公告）日：2022-03-10

  The present invention is directed to certain 2-aminoquinzaoline derivatives of Formula (I): and pharmaceutically acceptable salts thereof, wherein R1, R3, R4,X1, and X2 are as defined herein, which are potent inhibitors of LRRK2 kinase and may be useful in the treatment or prevention of diseases in which the LRRK2 kinase is involved, such as Parkinson's Disease and other diseases and disorders described herein. The invention is also directed to pharmaceutical compositions comprising these compounds and the use of these compounds and compositions in the prevention or treatment of such diseases in which LRRK-2 kinase is involved.

  本发明涉及公式（I）所示的某些2-氨基喹唑啉衍生物及其药学上可接受的盐，其中R1、R3、R4、X1和X2的定义如本文所述，这些衍生物是LRRK2激酶的有效抑制剂，可用于治疗或预防LRRK2激酶参与的疾病，例如帕金森病和其他本文所述的疾病和疾病。本发明还涉及包含这些化合物的制药组合物以及在预防或治疗LRRK-2激酶参与的这些疾病中使用这些化合物和组合物。
• Thiadiazole IRAK4 compounds
  申请人：Gilead Sciences, Inc.

  公开号：US11046686B2

  公开（公告）日：2021-06-29

  A compound of Formula (I): pharmaceutically acceptable salts thereof, deuterated analogs thereof, compositions thereof, and methods of treating disease using a compound thereof are disclosed.

  式 (I) 的化合物： 公开了其药学上可接受的盐、其氚代类似物、其组合物以及使用其化合物治疗疾病的方法。